Phytomedical compounds as promising therapeutic agents for COVID-19 targeting angiotensin-converting enzyme 2: a review

J Pharm Pharmacol. 2024 Oct 3;76(10):1239-1268. doi: 10.1093/jpp/rgae101.

Abstract

Aims: The aim of the present review was to highlight natural product investigations in silico and in vitro to find plants and chemicals that inhibit or stimulate angiotensin-converting enzyme 2 (ACE-2).

Background: The global reduction of incidents and fatalities attributable to infections with SARS-CoV-2 is one of the most public health problems. In the absence of specific therapy for coronavirus disease 2019 (COVID-19), phytocompounds generated from plant extracts may be a promising strategy worth further investigation, motivating researchers to evaluate the safety and anti-SARS-CoV-2 effectiveness of these ingredients.

Objective: To review phytochemicals in silico for anti-SARS-CoV-2 activity and to assess their safety and effectiveness in vitro and in vivo.

Methods: The present review was conducted using various scientific databases and studies on anti-SARS-CoV-2 phytochemicals were analyzed and summarized. The results obtained from the in silico screening were subjected to extraction, isolation, and purification. The in vitro studies on anti-SarcoV-2 were also included in this review. In addition, the results of this research were interpreted, analyzed, and documented on the basis of the bibliographic information obtained.

Results: This review discusses recent research on using natural remedies to cure or prevent COVID-19 infection. The literature analysis shows that the various herbal preparations (extracts) and purified compounds can block the replication or entrance of the virus directly to carry out their anti-SARS-CoV-2 effects. It is interesting to note that certain items can prevent SARS-CoV-2 from infecting human cells by blocking the ACE-2 receptor or the serine protease TMPRRS2. Moreover, natural substances have been demonstrated to block proteins involved in the SARS-CoV-2 life cycle, such as papain- or chymotrypsin-like proteases.

Conclusion: The natural products may have the potential for use singly or in combination as alternative drugs to treat/prevent COVID-19 infection, including blocking or stimulating ACE-2. In addition, their structures may provide indications for the development of anti-SARS-CoV-2 drugs.

Keywords: in silico; in vitro; COVID-19; RAAS; SARS-CoV-2; angiotensin-converting enzyme 2 (ACE-2); angiotensin-converting enzyme 2 inhibitors; angiotensin-converting enzyme 2 stimulators; medicinal plants; mode of action; natural products.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2* / antagonists & inhibitors
  • Angiotensin-Converting Enzyme 2* / metabolism
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • COVID-19
  • COVID-19 Drug Treatment*
  • Humans
  • Phytochemicals* / pharmacology
  • Phytochemicals* / therapeutic use
  • Phytotherapy
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • SARS-CoV-2* / drug effects

Substances

  • Angiotensin-Converting Enzyme 2
  • Phytochemicals
  • Antiviral Agents
  • Plant Extracts
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme Inhibitors

Grants and funding